Patents by Inventor Xiaolun Wang

Xiaolun Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRas G12D inhibitors
    Patent number: 12686692
    Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: July 21, 2026
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: Xiaolun Wang, Matthew Arnold Marx, Shelley Allen, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Michael Christopher Hilton, Dean Russell Kahn, Macedonio Junior Mejia, Phong Nguyen, Spencer Pajk, Martha E. Rodriguez, Pavel Yu Savechenkov, Tony Pisal Tang
  • KRAS G12D inhibitors
    Patent number: 12655160
    Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: June 16, 2026
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: Xiaolun Wang, Matthew Arnold Marx, John David Lawson, Shelley Allen, Patrick Michael Barbour, James Francis Blake, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Sherif Hosam Hassanien, Michael Christopher Hilton, Macedonio Junior Mejia, Jacob Matthew O'Leary, Tony Pisal Tang
  • KRas G12D inhibitors
    Patent number: 12630566
    Abstract: The present invention relates to methods of treating cancer with compounds that inhibit KRas G12D. In particular, the present invention relates to methods of treating non-small cell lung cancer, colorectal cancer, and pancreatic cancer by administering a compound of the following formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 23, 2024
    Date of Patent: May 19, 2026
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • SUBSTITUTED PYRIDOPYRIMIDINONES
    Publication number: 20260078120
    Abstract: Disclosed herein are substituted pyridopyrimidinones, methods for their preparation, and use thereof.
    Type: Application
    Filed: August 25, 2023
    Publication date: March 19, 2026
    Applicant: MIRATI THERAPEUTICS, INC.
    Inventors: JOHN MICHAEL KETCHAM, CHRISTOPHER RONALD SMITH, MATTHEW ARNOLD MARX, JOHN DAVID LAWSON, STEPHEN HARWOOD, AARON CRAIG BURNS, KERSTI CADDELL-HAATVEIT, KELLY ELAINE PEARSON, ATHENEA NOELANI GARDEN ALOIAU, JON KUEHLER, BRIANA BOBEK, ASHLEE HOPE WATKINS, BENJAMIN DONALD JONES, ANTHONY DAVID IVETAC, XIAOLUN WANG
  • TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS
    Publication number: 20260035389
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: August 13, 2025
    Publication date: February 5, 2026
    Inventors: Xiaolun WANG, Anthony IVETAC, Svitlana KULYK, John David LAWSON, Matthew Arnold MARX, Christopher Ronald SMITH
  • PAN-KRAS INHIBITORS
    Publication number: 20260015344
    Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: June 13, 2023
    Publication date: January 15, 2026
    Inventors: Svitlana KULYK, Xiaolun WANG
  • AZAQUINAZOLINE PAN-KRAS INHIBITORS
    Publication number: 20260015350
    Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: June 13, 2023
    Publication date: January 15, 2026
    Inventors: Xiaolun WANG, Svitlana KULYK, John David LAWSON, Matthew Arnold MARX, Christopher Ronald SMITH
  • AZAQUINAZOLINE PAN-KRAS INHIBITORS
    Publication number: 20250388606
    Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: June 2, 2025
    Publication date: December 25, 2025
    Inventors: Xiaolun WANG, Svitlana KULYK, John David LAWSON, Matthew Arnold MARX, Christopher Ronald SMITH
  • SALTS OF SOS1 INHIBITORS
    Publication number: 20250382290
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: June 23, 2023
    Publication date: December 18, 2025
    Applicant: MIRATI THERAPEUTICS, INC.
    Inventors: MATTHEW ARNOLD MARX, JOHN MICHAEL KETCHAM, CHRISTOPHER RONALD SMITH, JOHN DAVID LAWSON, AARON CRAIG BURNS, XIAOLUN WANG, SVITLANA KULYK, ANTHONY IVETAC
  • PRODRUGS OF PAN-KRAS INHIBITORS
    Publication number: 20250376483
    Abstract: The present invention relates to prodrugs of specific compounds that inhibits multiple mutated forms of KRas, i.e., the pan-KRas inhibitors. In particular, the present invention relates to prodrugs of these pan-KRas compound, pharmaceutical compositions comprising the prodrugs and methods of use therefor.
    Type: Application
    Filed: June 13, 2023
    Publication date: December 11, 2025
    Inventors: Matthew Arnold MARX, Rongliang CHEN, Xiaolun WANG
  • TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS
    Publication number: 20250368649
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: June 13, 2023
    Publication date: December 4, 2025
    Inventors: Xiaolun WANG, Anthony IVETAC, Svitlana KULYK, John David LAWSON, Matthew Arnold MARX, Christopher Ronald SMITH
  • Tetrahydropyridopyrimidine pan-KRas inhibitors
    Patent number: 12421253
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: April 24, 2024
    Date of Patent: September 23, 2025
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • SOS1 INHIBITORS
    Publication number: 20250270220
    Abstract: The present invention relates to methods of treating cancer using compounds that inhibit Son of sevenless homolog 1 (SOS1) activity and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 7, 2025
    Publication date: August 28, 2025
    Applicant: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang, Svitlana Kulyk, Anthony Ivetac
  • Azaquinazoline pan-KRas inhibitors
    Patent number: 12398154
    Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: August 26, 2025
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Xiaolun Wang, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • SOS1 INHIBITORS
    Publication number: 20250059182
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: June 21, 2022
    Publication date: February 20, 2025
    Inventors: John Michael Ketcham, Christopher Ronald Smith, Matthew Arnold Marx, Xiaolun Wang, Aaron Craig Burns, Svitlana Kulyk, Anthony Ivetac, John David Lawson
  • Bicyclic-fused heteroaryl or aryl compounds
    Patent number: 12202836
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.
    Type: Grant
    Filed: June 28, 2023
    Date of Patent: January 21, 2025
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS
    Publication number: 20240376127
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: April 24, 2024
    Publication date: November 14, 2024
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
    Publication number: 20240368153
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: June 29, 2022
    Publication date: November 7, 2024
    Inventors: Christopher Ronald Smith, Svitlana Kulyk, Matthew Arnold Marx, John David Lawson, Anthony Ivetac, Xiaolun Wang, Aaron Craig Burns
  • KRAS G12D INHIBITORS
    Publication number: 20240309020
    Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: April 23, 2024
    Publication date: September 19, 2024
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • Tetrahydropyridopyrimidine pan-KRas inhibitors
    Patent number: 11999753
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: June 4, 2024
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith